The test showed 94.4% accuracy and detected cases missed by imaging.
HerAnova Lifesciences presented clinical validation data for HerResolve, a blood-based test designed to aid in the diagnosis of endometriosis, at the 2026 Endocrine Society Annual Meeting.
The research, which was also published in the Journal of Minimally Invasive Gynecology, evaluated the test against laparoscopic visualization and histopathological confirmation. The study involved 298 women of reproductive age across multiple clinical sites.
HerResolve is a multi-omic blood test that integrates three microRNAs, three protein biomarkers, and one steroid hormone biomarker. These markers are quantified using qPCR and immunoassay technologies. The data, along with patient age and body mass index, are analyzed using an artificial intelligence-driven random forest machine-learning model to detect endometriosis, according to the company.
According to the study, the test demonstrated an area under the curve of 0.944, representing 94.4% accuracy. The validation performance also showed 80% sensitivity and 97.5% specificity. Notably, the test identified 61.5% of true positive cases that were missed by transvaginal ultrasound or MRI.
“These findings demonstrate the potential of a multi-omic approach to complement multimodal diagnostic pathways and help reliably identify endometriosis with high accuracy, including in patients whose disease may not be detected through imaging alone,” says Farideh Bischoff, PhD, chief medical officer of HerAnova Lifesciences, in a release. “We believe this approach can help shorten diagnostic delays and enable earlier treatment interventions.”
Diagnosis of endometriosis currently takes seven to 10 years because the clinical gold standard requires invasive laparoscopic surgery, according to a release from HerAnova Lifesciences. HerResolve was developed as a non-invasive triage tool to identify patients who may benefit from further evaluation—joining other diagnostic advancements such as saliva-based testing and blood-based diagnostics—reserving surgery for treatment rather than diagnosis.
“Every year of delayed diagnosis carries real consequences, worsening pain, declining fertility, and increasing healthcare burden,” says Penny Wan, chairwoman of HerAnova Lifesciences, in a release. “These results reinforce the important role molecular diagnostics can play in women’s health, and our commitment to providing clinicians with scalable, accessible tools that improve diagnostic confidence.”
HerAnova Lifesciences is currently conducting a prospective validation study across diverse patient populations to further refine the algorithm. The company is also performing longitudinal analyses to evaluate the assay’s utility in monitoring treatment response over time.
